Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) wit
- This topic has 0 replies, 1 voice, and was last updated 3 years, 11 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
https://meetinglibrary.asco.org/record/187835/abstract
Viewing 1 post (of 1 total)
- The forum ‘Clinical Trials’ is closed to new topics and replies.